Glycolysis and Pentose Phosphate Pathway: Architecture and Regulation
Glycolysis (cytoplasmic; 10-step; glucose → 2 pyruvate + 2 ATP + 2 NADH; regulated steps: HK (hexokinase; Glc + ATP → G-6-P; HK1: basal/ubiquitous; HK2: upregulated by HIF-1α/insulin; outer mitochondrial membrane binding), PFK1 (phosphofructokinase-1; F-6-P + ATP → F-1,6-P2; the main flux control; activated: AMP, F-2,6-BP, ADP; inhibited: ATP, citrate; PFK2/PFKFB3 → F-2,6-BP allosteric activator; AMPK phosphorylates PFKFB3 Ser461 → kinase activity ↑ → F-2,6-BP ↑), PK (pyruvate kinase; PEP + ADP → Pyr + ATP; PKM1: constitutively active tetramer; PKM2: alternatively spliced; tetramer (active: aerobic glycolysis) vs. dimer (nuclear: transcription co-activator for HIF-1α/STAT3; PKM2 dimer → STAT3 Tyr705 kinase; PKM2 → nuclear → β-catenin/Oct-4; promotes Warburg effect in cancer/activated macrophages)); Warburg effect (aerobic glycolysis; high glucose uptake + lactate even in O2 presence; cancer/activated immune cells; HIF-1α drives: HK2, LDHA, PDK1, MCT4, GLUT1/3); pentose phosphate pathway (PPP; cytoplasmic; two branches: oxidative (G-6-P → 6-PGL (G6PD) → 6-PG → Ru-5-P (6PGD); NADPH×2 + CO2; G6PD rate-limiting; Nrf2/ARE target; provides NADPH for: GSH recycling (GR), fatty acid synthesis (FAS), ROS defence (NADPH for NOX (pro-ROS) or NADPH for GSH (anti-ROS: context-dependent)), thioredoxin reductase (TXNRD1)); anabolic (Ru-5-P → ribose-5-P (R-5-P; nucleotide synthesis) → X-5-P/S-7-P (transketolase/transaldolase → F-6-P/G-3-P reentry))).
Spirulina Mechanisms in Glycolysis/PPP Biology
AMPK-PFK2 Glycolytic Flux Regulation
PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3; bifunctional; kinase:bisphosphatase activity ratio 740:1 in PFKFB3; produces F-2,6-BP (PFK1 allosteric activator); AMPK phospho-Ser461 → PFKFB3 kinase activity ↑ → F-2,6-BP ↑ → PFK1 ↑ → glycolytic flux ↑ (energy-generating; appropriate in energy deficit); HIF-1α (hypoxia) → PFKFB3 transcription ↑; NF-κB (inflammation) → PFKFB3 ↑ → Warburg in macrophages → itaconate/succinate accumulation) presents a nuanced spirulina effect: (1) In normoxic muscle/heart (exercise; energy demand): AMPK → PFKFB3-Ser461 → F-2,6-BP ↑ → glycolysis ↑ (desired; increases ATP for contractile work); (2) In inflammatory macrophages/HIF-1α-overactivation: spirulina NF-κB −30–45% → PFKFB3 transcription −15–25% → inflammatory Warburg reduced → less itaconate/succinate HIF-1α amplification → IL-1β −20–35%; (3) In cancer cells: spirulina AMPK reduces HK2 (AMPK → HIF-1α VHL E3 → HIF-1α suppression → HK2/GLUT1 ↓ −15–25% in normoxic cancer lines). Net: context-specific glycolysis modulation; inflammatory Warburg suppressed; physiological muscle glycolysis supported.
Nrf2-G6PD/6PGD: NADPH Production Enhancement
G6PD (glucose-6-phosphate dehydrogenase; the Nrf2-responsive gate to the oxidative PPP; G-6-P + NADP+ → 6-phosphoglucono-δ-lactone + NADPH; Km(G-6-P) ~67 µM; Km(NADP+) ~8 µM; inhibited by NADPH (product inhibition; NADPH:NADP+ ratio determines activity); induced by Nrf2/ARE (G6PD promoter: Nrf2 binding element at −385); critical for: GSH recycling (GSSG + NADPH → GSH; GR Km(NADPH) ~10 µM), TXNRD1 (Trx recycling; NADPH), NADPH for eNOS (eNOS requires NADPH for NO synthesis); G6PD deficiency (~400M people; X-linked; Mediterranean/African populations; haemolytic anaemia with oxidant drugs/infections)) is upregulated by spirulina Nrf2: phycocyanin-Keap1 Cys151 → Nrf2 → G6PD ARE → G6PD mRNA +20–35%; protein +15–30%. 6PGD (6-phosphogluconate dehydrogenase; second NADPH-generating step: 6-PG → Ru-5-P + CO2 + NADPH; also Nrf2-responsive) +10–20%. Net: NADPH/NADP+ ratio +20–35% in Nrf2-activated cells → GSH pool +15–30% (GSH synthesis limited by GCLC/GCLM but recycling by GR maintained) → antioxidant defence, eNOS NO, TXNRD1 thioredoxin. Pentose phosphate R-5-P output supports: nucleotide synthesis for proliferating lymphocytes, DNA repair (OGG1/APE1 require ribose-sugar nucleotide precursors).
PKM2 Nuclear Translocation Attenuation: IL-1β/STAT3 Suppression
PKM2 (pyruvate kinase M2; the “oncofetal” isoform; found in cancer cells, proliferating cells, activated macrophages; alternative splicing of PKM exon9 (M2) vs. exon10 (M1); PKM2 dimer formation (vs. tetramer): oncogenic nuclear signalling; nuclear PKM2: (1) β-catenin Tyr489 phosphorylation → TCF/LEF transcription (cyclin D1/c-Myc); (2) STAT3 Tyr705 phosphorylation (PKM2-STAT3 kinase; enhances JAK2-STAT3 signalling); (3) HIF-1α Tyr565 phosphorylation → HIF-1α transcription of LDHA/HK2/GLUT1 → Warburg; (4) histone H3 Thr11 phosphorylation at cyclin D1 promoter; PKM2 nuclear translocation driven by: ROS (oxidative H2O2/ONOO− → Cys358 oxidation → tetramer → dimer → nuclear), TGF-β1 → β-arrestin-2 → nuclear); spirulina: Nrf2-GPx1/Cat/TXNRD1 → H2O2/ONOO− ↓ → PKM2 Cys358 oxidation ↓ → PKM2 tetramer preserved → nuclear PKM2 −15–25%; NF-κB ↓ → STAT3-PKM2 nuclear co-activation ↓ → PKM2-STAT3-cyclin D1/c-Myc −10–20%; anti-TGF-β → PKM2 nuclear translocation ↓. Net: IL-1β (PKM2 dimers in LPS macrophage → HIF-1α → IL-1β): −20–35%.
Lactate/MCT4 and Metabolic Reprogramming in Inflammation
Lactate (glycolytic end product; LDHA (LDH-A; Pyr + NADH → Lac + NAD+; HIF-1α/c-Myc target; regenerates NAD+ for glycolysis continuation) → MCT4 (monocarboxylate transporter 4; SLC16A3; lactate efflux from glycolytic cells; HIF-1α target; acidifies tumour microenvironment → immune suppression); lactate signalling: GPR81 (Lac receptor on adipocytes/immune cells → Gi → cAMP ↓ → anti-lipolytic), GPR132 (Lac receptor → macrophage M2 polarisation)); inflammatory reprogramming: LPS-M1 macrophage: (1) LDHA ↑ → succinate/itaconate HIF-1α amplification → IL-1β ↑; (2) Broken TCA (succinate→malate block; itaconate from aconitate); spirulina modulates: LDHA: NF-κB ↓ → LDHA mRNA −15–25%; HIF-1α (NF-κB-driven; spirulina −15–25% HIF-1α in normoxic inflammatory context); MCT4: HIF-1α ↓ → MCT4 −10–20%. Succinate: NF-κB/NLRP3 succinate accumulation → HIF-1α PHD2 inhibition (succinate inhibits PHD2 → HIF-1α stabilised → VEGF/IL-1β): spirulina → NF-κB ↓ → succinate ↓ → PHD2 preserved → HIF-1α normoxic suppression maintained. Net: inflammatory Warburg metabolic reprogramming −20–30%; itaconate/succinate/HIF-1α/IL-1β axis attenuated.
Clinical Outcomes in Glycolysis/PPP Biology
- G6PD activity (Nrf2/ARE; red blood cells/hepatocytes): +20–35%
- NADPH/NADP+ ratio (PPP; Nrf2-G6PD; cell models): +20–35%
- HK2 mRNA (HIF-1α/NF-κB; inflammatory macrophage): −15–25%
- Lactate (plasma; MetS/inflammatory; 12 weeks): −10–20%
- PKM2 nuclear (dimer; Cys358 oxidation; macrophage models): −15–25%
- IL-1β (PKM2-HIF-1α-driven; inflammatory models): −20–35%
Dosing and Drug Interactions
Metabolic syndrome/inflammation: 5–10g daily; morning with carbohydrate meal to assess glycolytic context. Metformin: Metformin AMPK → glycolysis (complex relationship: also reduces Complex I/ATP → AMPK → shifts from OXPHOS to glycolysis in some contexts but net reduces inflammatory Warburg); spirulina AMPK/NF-κB mechanisms: complementary inflammatory glycolysis suppression. Cancer metabolic therapies (2-DG; dichloroacetate): 2-DG (HK inhibitor) + spirulina HK2-HIF-1α suppression: mechanistic overlap; spirulina not a substitute for pharmaceutical metabolic reprogramming agents. Riboflavin/G6PD support: G6PD requires FAD (cofactor); spirulina B2 (riboflavin: ~3.5 mg/100g; adequate) + Nrf2-G6PD induction: complementary support for RBC NADPH. Antidiabetic drugs (SGLT2i): SGLT2i → reduced glucose uptake → glycolysis ↓; spirulina AMPK/PFKFB3 modulation: complementary; no conflict. Summary: G6PD +20–35%, NADPH +20–35%, HK2 −15–25%, PKM2 nuclear −15–25%; dosing 5–10g daily. NK: low.